Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

View Full Paper
Ask AI
Bookmark
Share

Authors

FVFranceso VersinoKing's College HospitalEGEmmanuel GnanamanickamUniversity of South AustraliaFAFrances AldridgeKing's College Hospital

Discussion

Loading...

Member takes

Implication

International study reveals comparable poor survival in TP53-non-mutated myeloid neoplasms with 17p loss, suggesting need for revised classifications.

Key Points

  • Median overall survival for 17p loss in TP53-non-mutated cases was 10.2 months, akin to TP53-mutated disease at 8.7 months.
  • 1% of the screened 8876 TP53-non-mutated myeloid neoplasms displayed 17p loss, representing a significant finding in this cohort.
  • Evaluation of karyotype data and SNP array helped confirm a high incidence of structural TP53 abnormalities.
  • Study findings advocate for the inclusion of 17p loss cases in future disease classifications for better risk stratification.

Cite This Study

Versino et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d84ehttps://doi.org/10.1182/blood-2025-3858
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression2025
  2. 217p cytogenetic changes in TP53-mutated AML2025
  3. 3Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation2025
  4. 4Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  5. 5Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type2025 · 4 citations